News & Press Releases

Mintz has again been ranked by Patexia, a leading intellectual property platform, in its Intelligence Report, a comprehensive list of the “best performing” and “most active” ITC Section 337 attorneys and law firms. 

Law360 Pulse featured Mintz’s addition of the five-partner antitrust litigation team led by Philip Iovieno and including Nicholas Gravante, Jr., Sean O’Shea, Michael Petrella, and Matthew Karlan.

Sige Gutman, Life Sciences Litigation Practice Chair, shared insights with IAM in an article about a decision by the US District Court for the District of Delaware which found that a gene therapy patent of RegenxBio and the Trustees of the University of Pennsylvania was ineligible and granted summary judgement in favor of Sarepta Therapeutics.  

Mintz has been named a finalist for three awards by LSPN. The awards celebrate excellence across the industry, from trailblazing individuals to firms redefining the boundaries of life sciences IP.  

Mergermarket recently featured insights from Cheryl Reicin, Life Sciences Practice Co-chair, in an article discussing a potential 2026 rebound in M&A activity across the contract development and manufacturing organization (CDMO) sector, which provides outsourced development and manufacturing services to biopharma and medical‑device companies. 

Mintz advised the underwriters in connection with Eupraxia Pharmaceuticals’ $63.2 million public offering.